Niagen Bioscience
NAGE
101 hedge funds and large institutions have $201M invested in Niagen Bioscience in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
88% more call options, than puts
Call options by funds: $7.43M | Put options by funds: $3.95M
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
5% more funds holding
Funds holding: 96 → 101 (+5)
5% less capital invested
Capital invested by funds: $211M → $201M (-$9.98M)
3.82% less ownership
Funds ownership: 33.84% → 30.02% (-3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$6.76M |
| 2 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$2.34M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.32M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.81M |
| 5 |
State Street
Boston,
Massachusetts
|
+$926K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.03M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$6.97M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$5.19M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$3.24M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.24M |
NAGE Hedge Fund Activity: Q2 2021 in Review
101 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2021, worth a combined $201M — down 4.7% from $211M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NAGE positions and 14 closed out — a net gain of 5 holders — while 37 added to existing stakes and 28 trimmed.
The largest buyer was Barclays, adding an estimated $6.76M. The largest seller was Millennium Management, cutting an estimated $7.03M.
- 101 institutional investors held Niagen Bioscience (NAGE) as of Q2 2021, up from 96 in Q1 2021.
- Funds reported $201M of Niagen Bioscience stock for Q2 2021, down 4.7% quarter-over-quarter.
- 19 funds opened new Niagen Bioscience positions in Q2 2021 and 14 closed out, a net change of +5 holders.
- The largest Niagen Bioscience buyer in Q2 2021 was Barclays, an estimated $6.76M added.
- The largest Niagen Bioscience seller in Q2 2021 was Millennium Management, an estimated $7.03M sold.
Based on aggregated 13F filings for Q2 2021.